Newly launched Polk Collaborative aims to integrate the arts with health
Modeled after the national NeuroArts Blueprint, an initiative from Johns Hopkins University and Aspen Institute, PAHC opens with a Lakeland Chapter, Watson Clinic said in a news release. The Watson Clinic Foundation's Arts in Medicine program will serve in the new alliance.
'We are proud to align our local vision with the momentum of the national NeuroArts movement,' Tiffany Van Wieren, the Watson Clinic Foundation's Arts in Medicine Program Coordinator, said in the release. 'This collaborative will amplify existing efforts while also inviting new partners to explore how creative expression can support healing, resilience, and connection in our community while also elevating the research behind this movement.'
Joining the Watson Clinic Foundation's Arts in Medicine Program in the initiative are the Ashley Gibson Barnett Museum of Art, Florida Southern College, Lakeland Vision, Lakeland Volunteers in Medicine, Lakeland Symphony Orchestra, Orlando Health, Mayor's Council on the Arts and the Polk Arts and Cultural Alliance.
The initial phase of PAHC will focus on identifying programs, individuals and institutions currently integrating arts and health throughout Polk County, the release said. The mission of PAHC will not only recognize existing work but will also serve as a gateway for curious individuals and organizations to learn about NeuroArts and to join the collaborative, sparking fresh initiatives and innovative partnerships in previously unengaged sectors.
Any organization or individual with interest in joining the collaborative should contact Tiffany Van Wieren at 863-603-4718 or AIM@WatsonClinic.com. For more information on PAHC, visit PolkArtsandHealth.org.
This article originally appeared on The Ledger: Polk Arts & Health Collaborative launches Arts in Medicine program
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival
Yahoo
3 hours ago
- Yahoo
State Department Halts Medical Visas For Palestinians
Eight Palestinian children from Gaza named, Rahaf, Ibrahim, Jana, Mustafa, Nasser, Mohammed, Kenan, and Ahmed, arrive at O'Hare International Airport, sponsored by Palestine Children's Relief Fund (PCRF), for medical treatment in Chicago, Illinois, USA on December 2, 2024. Credit - Jacek Boczarski—Anadolu via Getty Images The State Department said it would stop issuing visas to Palestinians from Gaza, including to those coming to the United States for humanitarian and medical treatment, following a campaign by far-right political activist Laura Loomer. 'All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days,' the U.S. State Department said in a statement on Saturday. The decision will impact several programs that have evacuated dozens of critically injured children from Gaza over the last 21 months, including amputees and severe burn victims. The announcement came just hours after a series of social media posts from Loomer criticizing the medical evacuations of Palestinian children to the U.S. In one post, she shared a video of a child amputee arriving in a wheelchair at Seattle airport for medical treatment, adding: 'The Trump administration needs to shut this abomination down ASAP.' Loomer, who once described herself as a 'proud Islamaphobe' and said 9/11 was an 'inside job,' made false claims in her posts and said she had sent her 'evidence' to Secretary of State Marco Rubio. Hours later, the pause was announced. Read more: I Can No Longer Feed Kids in Gaza Rubio told "Face the Nation" on CBS on Sunday that the action came after "outreach from multiple congressional offices asking questions about it." But Loomer quickly took credit for the pause, posting: 'It's amazing how fast we can get results from the Trump administration.' The Palestinian Children Relief Fund (PCRF), a charity that organizes medical evacuations of children to the U.S., said the move will prevent them from providing 'lifesaving medical treatment' for 'critically ill children' from Gaza. 'Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza,' the PCRF said in a statement. According to the World Health Organization (WHO), Gaza's health system has been in collapse, and there has been a 'relentless and systematic decimation of hospitals in Gaza.' The United Nations children's charity, UNICEF, said in July that more than 17,000 children have been killed and 33,000 injured in Gaza in the last 21 months. HEAL Palestine, another charity that organizes evacuations and which was specifically targeted by Loomer in her posts, said this month it has evacuated 63 injured children and 148 total evacuees to the U.S. to receive treatment. Earlier this month, it carried out the largest known evacuation of wounded children from Gaza to the U.S., which included 11 children and their families, most of them for treatment of amputations. HEAL Palestine made it clear on social media that the visas it uses to bring people to the U.S. for treatment were not for resettlement, but for lifesaving care, contrary to Loomer's claims. 'After their treatment is complete, the children and any accompanying family members return to the Middle East. This is a medical treatment program, not a refugee resettlement program,' HEAL Palestine said Saturday. The charity added that U.S. tax dollars do not fund the treatment provided to these children. Loomer, a conspiracy theorist with a history of using hate speech to gain attention, has acquired an outsized influence over the White House in President Donald Trump's second term. She has successfully lobbied to remove people from top government roles whom she considers disloyal to the president, including six from the National Security Council, a senior Customs and Border Protection official, and a Food and Drug Administration vaccine official. TIME has contacted the State Department for comment. Contact us at letters@ Solve the daily Crossword
